The ROE as of September 2024 (TTM) for GT Biopharma, Inc. (GTBP) is -160.47%

According to GT Biopharma, Inc.’s latest financial reports and current stock price. The company's current ROE is -160.47%. This represents a change of 269.37% compared to the average of -43.45% of the last 4 quarters.

GT Biopharma, Inc. (GTBP) Historical ROE (quarterly & annually)

How has GTBP ROE performed in the past?

The mean historical ROE of GT Biopharma, Inc. over the last ten years is -250.54%. The current -160.47% ROE has changed -35.95% with respect to the historical average. Over the past ten years (40 quarters), GTBP's ROE was at its highest in in the September 2019 quarter at 164.92%. The ROE was at its lowest in in the September 2018 quarter at -1748.87%.

GT Biopharma, Inc. (GTBP) ROE by Quarter and Year

Discovering the peaks and valleys of GT Biopharma, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

GT Biopharma, Inc. (GTBP) Average ROE

How has GTBP ROE performed in the past?

The current ROE of GT Biopharma, Inc. (GTBP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

GT Biopharma, Inc. (GTBP) ROE vs. Peers

How is GTBP’s ROE compared to its peers?

GT Biopharma, Inc.’s ROE is greater than Allarity Therapeutics, Inc. (-704.78%), greater than NeuroBo Pharmaceuticals, Inc. (-154.04%), greater than Hillstream BioPharma, Inc. (-47249.59%), greater than Virax Biolabs Group Limited (-115.10%), greater than Quoin Pharmaceuticals, Ltd. (-112.11%), less than Panbela Therapeutics, Inc. (545.45%), greater than Virpax Pharmaceuticals, Inc. (-1554.74%), greater than Revelation Biosciences, Inc. (-243.91%), greater than Biodexa Pharmaceuticals Plc (-141.90%), greater than Praxis Precision Medicines, Inc. (-61.47%), greater than Pulmatrix, Inc. (-61.78%), greater than Oncorus, Inc. (-130.61%), less than Akari Therapeutics, Plc (1.04%), greater than Sonnet BioTherapeutics Holdings, Inc. (-398.33%), greater than Landos Biopharma, Inc. (-73.00%), less than Cingulate Inc. (11.47%), greater than SAB Biotherapeutics, Inc. (-94.04%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), greater than Cadrenal Therapeutics, Inc. Common Stock (-93.71%), greater than Monopar Therapeutics Inc. (-110.60%), greater than Protara Therapeutics, Inc. (-55.03%), less than Vaccinex, Inc. (1.11%), greater than Miromatrix Medical Inc. (-119.21%), greater than Surrozen, Inc. (-178.66%),

Build a custom stock screener for GT Biopharma, Inc. (GTBP) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GT Biopharma, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

GT Biopharma, Inc. (GTBP) and other stocks custom spreadsheet templates

The easiest way to analyze a company like GT Biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.